I obtained my BSc. in Biochemistry at York in 2002, going on to study a Ph.D. in Parasitology, also at York. As a post-doc, I worked at the Wellcome Sanger Institute, before moving to Abcam in 2010. I was promoted to the Abcam’s Head of R&D in 2013, where I had a broad set of responsibilities, spanning science, business and IP. The core of my role focused on development of novel immune-reagents and assays, working with teams across the globe, and across biology and chemistry. I worked closely with commercial teams to build business cases that set company R&D strategy, as well as providing technical due diligence for acquisitions and IP. My remit included internal, post-acquisition, and external tech transfer. With regard to the former, I oversaw the transfer of Abcam's EU CRO activities from the US to the UK. I have now returned to the Wellcome Sanger Institute to apply my industrial experience by helping scientists commercialise and share their ideas for the benefit of society.
View Gary's articles on LinkedIn